A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202) (NCT07361510)

🧪 Interventions in This Study

• Pumitamig (DRUG)
• Pembrolizumab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (278 Sites)

Showing the first 25 of 278 sites.

• Southern Cancer Center Pc — Daphne, Alabama
• Mohtaseb Cancer Center & Blood Disorders — Bullhead City, Arizona
• Palo Verde Hematology Oncology — Glendale, Arizona
• Local Institution - 0407 — Anaheim, California
• Local Institution - 0352 — Beverly Hills, California
• Orange Coast Memorial Medical Center — Fountain Valley, California
• Local Institution - 0027 — Los Alamitos, California
• Local Institution - 0422 — Los Angeles, California
• Local Institution - 0403 — Oakland, California
• Local Institution - 0208 — Pleasant Hill, California
• BASS Cancer Center — Walnut Creek, California
• Local Institution - 0340 — Lakewood, Colorado
• Clermont Oncology Center — Clermont, Florida
• Advanced Research — Coral Springs, Florida
• BRP- Hialeah Hospital — Hialeah, Florida
• Florida Clinical Trials Group — Tamarac, Florida
• University Cancer & Blood Center, LLC — Athens, Georgia
• Local Institution - 0412 — Augusta, Georgia
• Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital — Marietta, Georgia
• Local Institution - 0423 — Urbana, Illinois
• Northwest Cancer Centers, P.C. — Dyer, Indiana
• Missouri Cancer Associates — Columbia, Missouri
• Local Institution - 0224 — Laurelton, New York
• Memorial Sloan Kettering Cancer Center — New York, New York
• Optum Medical Care, PC — Westbury, New York

📞 Contact the Study Coordinator

Phone: (855) 907-3286

Email: Clinical.Trials@bms.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Non-Small Cell Lung Cancer (NSCLC)

• Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) — Oakland, California
• HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer — Santa Monica, California
• PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung — Tampa, Florida
• U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer — Duarte, California
• Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC — Duarte, California
• Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) — Birmingham, Alabama

Explore by condition: All Non-Small Cell Lung Cancer (NSCLC) clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.